January 10, 2025 10:45 AM ESTUpdated January 10, 07:10 PM

Stemson Therapeutics shutters; Insilico teams up again with Menarini

ENDPOINTS

Plus, news about Crinetics, Compass Pathways, Amylyx Pharmaceuticals, Mersana Therapeutics, Guggenheim Partners, Sciwind Biosciences, 4D Molecular Therapeutics, Barinthus Bio, Y-mAbs Therapeutics and Meiji Seika Pharma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stemson Therapeutics shutters; Insilico teams up again with Menarini

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Stem­son Ther­a­peu­tics shut­ters; In­sil­i­co teams up again with Menar­i­ni

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Stemson Therapeutics shutters; Insilico teams up again with Menarini